AI assistant
STADA Arzneimittel AG — M&A Activity 2014
Jun 30, 2014
412_rns_2014-06-30_abd8ae7b-00d9-4475-91c6-89db47d19bdc.html
M&A Activity
Open in viewerOpens in your device viewer
News Details
Corporate | 30 June 2014 10:27
STADA Arzneimittel AG: STADA strengthens its branded product portfolio by purchasing the Flexitol(R) rights for UK and Ireland – a dermatological range in the area of hand and foot care
STADA Arzneimittel AG / Key word(s): Miscellaneous
30.06.2014 / 10:27
Press Release
STADA strengthens its branded product portfolio by purchasing the Flexitol(R) rights for UK and Ireland – a dermatological range in the area of hand and foot care
Bad Vilbel, June 30, 2014 – The British affiliate of STADA Arzneimittel AG, Thornton & Ross Ltd., purchased the production and distribution rights for the Flexitol(R) brand product portfolio in the United Kingdom and Ireland.
The net purchase price for the rights to the Flexitol(R) product range is 10 million pounds sterling (approximately Euro 12.49 million at current exchange rates) payable in cash subject to adjustments for inventory. The sellers are the LaCorium group of companies based in Sydney, Australia. The purchase does not include any production facilities. In order to optimize cost of sales, it is planned to transfer the production of nearly all of the products sold in UK and Ireland to Thornton & Ross’ in house manufacturing facilities.
The product package comprises 15 prescription-free (OTC) and prescribable (OTX) products in the area of hand and foot care. In 2013, net sales generated in the United Kingdom and Ireland with this dermatological range was approximately 3.3 million pounds sterling (approximately Euro 4.1 million at current exchange rates). In 2013 the Flexitol(R) product portfolio posted an EBITDA margin which is significantly above the average in the STADA Group.
“The acquisition of the Flexitol(R) dermatological range fits perfectly with our strategy of further accelerating the expansion of attractive-margin branded products. We will benefit from the purchase in terms of product sales in the United Kingdom and Ireland”, says Hartmut Retzlaff, Chairman of the Executive Board of STADA Arzneimittel AG. “Another interesting point of the acquisition is that the strongest selling product in the United Kingdom is positioned in the prescribable area and is included in the reimbursement list of the National Health Service in the United Kingdom”, adds Retzlaff.
Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2-18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506 / e-mail: [email protected]
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2-18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-506 / e-mail: [email protected]
Or visit us in the Internet at http://www.stada.com .
End of Corporate News
30.06.2014 Dissemination of a Corporate News, transmitted by DGAP – a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
| Language: | English |
| Company: | STADA Arzneimittel AG |
| Stadastraße 2-18 | |
| 61118 Bad Vilbel | |
| Germany | |
| Phone: | +49 (0)6101 603- 113 |
| Fax: | +49 (0)6101 603- 506 |
| E-mail: | [email protected] |
| Internet: | www.stada.de |
| ISIN: | DE0007251803, DE0007251845, |
| WKN: | 725180, 725184, |
| Indices: | MDAX |
| Listed: | Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard); Freiverkehr in Berlin, Hamburg, Hannover, München, Stuttgart |
| End of News | DGAP News-Service |
| - - - |
| 275779 30.06.2014 |